

## SUMMARY

In one example, the present disclosure provides a protein that binds an extracellular part of a membrane associated member of: the epidermal growth factor (EGF) receptor family or cMET; and an extracellular part of a membrane associated member of a WNT signaling pathway.

In one aspect, the present disclosure refers to a bispecific antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of a membrane associated member of the epidermal growth factor (EGF) receptor family and a variable domain that binds an extracellular part of a membrane associated member of a WNT-signaling pathway, wherein the bispecific antibody or functional part, derivative and/or analogue thereof comprises variable domains that bind EGFR and LGR5.

In another aspect, the present disclosure refers to the bispecific antibody or functional part, derivative and/or analogue thereof as disclosed herein, for use in the treatment of an individual that has cancer.

In yet another aspect, the present disclosure refers to use of the bispecific antibody or functional part, derivative and/or analogue thereof disclosed herein, in the manufacture of a medicament for treating cancer.

In yet another aspect, the present disclosure refers to a cell system comprising the bispecific antibody or functional part, derivative and/or analogue thereof disclosed herein, and a cell that expresses a membrane associated member of the epidermal growth factor (EGF) receptor family and that expresses a membrane associated member of the WNT pathway.

In yet another aspect, the present disclosure refers to an *in vitro* method for inhibiting proliferation of a cell that expresses a membrane associated member of the epidermal growth factor (EGF) receptor family and that expresses a membrane associated member of the WNT pathway in a system permissive for proliferation of the cell, the method comprising providing the system with the bispecific antibody disclosed herein.

Claims

1. A bispecific antibody or a functional part, derivative and/or analogue thereof  
5 that comprises a variable domain that binds an extracellular part of a membrane  
associated member of the epidermal growth factor (EGF) receptor family and a  
variable domain that binds an extracellular part of a membrane associated  
member of a WNT-signaling pathway, wherein  
the bispecific antibody or functional part, derivative and/or analogue thereof  
10 comprises variable domains that bind EGFR and LGR5.
2. The bispecific antibody or functional part, derivative and/or analogue  
thereof of claim 1, comprising a variable domain that binds EGFR and a variable  
domain that binds LGR5
- 15 - wherein the VH chain of the variable domain that binds EGFR comprises  
the amino acid sequence of VH chain MF3755 as depicted in Figure 1; or the amino  
acid sequence of VH chain MF3755 as depicted in Figure 1 having at most 15,  
preferably not more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 and preferably having not more  
than 5, 4, 3, 2 or 1 amino acid insertions, deletions, substitutions or a combination  
20 thereof with respect said VH; and
- wherein the VH chain of the variable domain that binds LGR5 comprises  
the amino acid sequence of VH chain MF5816 as depicted in Figure 1; or the amino  
acid sequence of VH chain MF5816 as depicted in Figure 1 having at most 15,  
preferably not more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 and preferably having not more  
25 than 5, 4, 3, 2 or 1 amino acid insertions, deletions, substitutions or a combination  
thereof with respect said VH..
3. The bispecific antibody or functional part, derivative and/or analogue  
thereof of claims 1 or 2, for use in the treatment of an individual that has cancer.

4. Use of the bispecific antibody or functional part, derivative and/or analogue thereof according to claim 1 or 2, in the manufacture of a medicament for treating cancer.
- 5 5. The use according to claim 4, wherein the cancer is an adenocarcinoma.
6. The use according to claim 4, wherein the cancer is Colorectal cancer; Pancreatic cancer; Lung cancer; Breast cancer; Liver cancer; Prostate cancer; Ovarian cancer; Cervical cancer; Endometrial cancer; Head and Neck cancer; 10 Melanoma; Testis cancer; Urothelial cancer; Renal cancer; Stomach cancer; or Carcinoid cancer.
7. The use according to claim 4, wherein the cancer is Colorectal cancer.
- 15 8. A cell system comprising the bispecific antibody or functional part, derivative and/or analogue thereof according to claim 1 or 2, and a cell that expresses a membrane associated member of the epidermal growth factor (EGF) receptor family and that expresses a membrane associated member of the WNT pathway.
- 20 9. An *in vitro* method for inhibiting proliferation of a cell that expresses a membrane associated member of the epidermal growth factor (EGF) receptor family and that expresses a membrane associated member of the WNT pathway in a system permissive for proliferation of the cell, the method comprising providing 25 the system with the bispecific antibody according to claim 1 or 2.